$136 Million is the total value of Omega Fund Management, LLC's 13 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TBIO | New | Translate Bio | $30,836,000 | – | 2,437,601 | +100.0% | 22.75% | – |
| PRTK | Paratek Pharmaceuticals | $26,524,000 | -21.5% | 2,600,410 | 0.0% | 19.57% | -41.1% | |
| OBSV | Sell | ObsEva | $15,135,000 | +12.2% | 999,664 | -0.0% | 11.17% | -15.8% |
| KZR | New | Kezar Life Sciences | $11,994,000 | – | 693,272 | +100.0% | 8.85% | – |
| SNNAQ | Sienna Biopharmaceuticals | $11,523,000 | -19.1% | 758,610 | 0.0% | 8.50% | -39.3% | |
| FGEN | FibroGen | $8,178,000 | +35.5% | 130,646 | 0.0% | 6.03% | +1.7% | |
| CDTX | Buy | Cidara Therapeutics | $7,846,000 | +340.8% | 1,508,794 | +239.1% | 5.79% | +231.0% |
| CBAY | CymaBay Therapeutics | $7,401,000 | +3.3% | 551,477 | 0.0% | 5.46% | -22.4% | |
| Sell | ESSA Pharma | $4,122,000 | 0.0% | 1,084,848 | -95.0% | 3.04% | -24.9% | |
| JNCE | Jounce Therapeutics | $4,060,000 | -65.7% | 529,965 | 0.0% | 3.00% | -74.3% | |
| PIRS | Pieris Pharmaceuticals | $3,946,000 | -25.7% | 778,230 | 0.0% | 2.91% | -44.2% | |
| DRNA | Dicerna Pharmaceuticals | $2,737,000 | +28.1% | 223,457 | 0.0% | 2.02% | -3.8% | |
| EGLTQ | Egalet | $1,220,000 | -33.0% | 2,889,926 | 0.0% | 0.90% | -49.7% | |
| JUNO | Exit | Juno Therapeutics | $0 | – | 0 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-02
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Replimune Group | 24 | Q2 2024 | 47.2% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Morphic Holding | 21 | Q2 2024 | 22.0% |
| Immunic Inc | 21 | Q2 2024 | 9.0% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.